Inovio Pharmaceuticals (INO) News Today $5.28 -0.28 (-5.04%) (As of 10/31/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Analysts Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) PT at $43.80October 26, 2024 | americanbankingnews.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Moderate Buy" by AnalystsInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five analysts that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and three have issued a buy recommOctober 23, 2024 | marketbeat.comInovio’s INO-3107 shows efficacy in recurrent respiratory papillomatosisOctober 22, 2024 | markets.businessinsider.comINOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRPOctober 21, 2024 | prnewswire.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Short Interest UpdateInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) was the target of a large growth in short interest in September. As of September 30th, there was short interest totalling 3,340,000 shares, a growth of 9.5% from the September 15th total of 3,050,000 shares. Currently, 13.0% of the shares of the stock are sold short. Based on an average daily volume of 329,200 shares, the days-to-cover ratio is currently 10.1 days.October 16, 2024 | marketbeat.comInovio Pharmaceuticals (NASDAQ:INO) Stock, Short Interest ReportOctober 8, 2024 | benzinga.comInovio Pharmaceuticals Inc. stock outperforms competitors despite losses on the dayOctober 5, 2024 | marketwatch.comInovio Pharmaceuticals (NASDAQ:INO) Price Target Lowered to $7.00 at Royal Bank of CanadaRoyal Bank of Canada lowered their price target on Inovio Pharmaceuticals from $8.00 to $7.00 and set a "sector perform" rating on the stock in a research report on Friday.October 4, 2024 | marketbeat.comINOVIO Reports Inducement Grants Under Inducement PlanOctober 2, 2024 | prnewswire.comINOVIO to Present at Upcoming Scientific ConferencesOctober 1, 2024 | prnewswire.comInovio Pharmaceuticals: Takes Another Torpedo But Keeps On SailingSeptember 30, 2024 | seekingalpha.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five analysts that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and three haSeptember 28, 2024 | marketbeat.comINOVIO to Present at Upcoming Scientific ConferenceSeptember 17, 2024 | prnewswire.comInovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gainsSeptember 16, 2024 | marketwatch.comInovio Pharmaceuticals Inc. stock rises Tuesday, still underperforms marketSeptember 11, 2024 | marketwatch.comInovio Pharmaceuticals, Inc. (GBM.F)September 3, 2024 | finance.yahoo.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of "Moderate Buy" by BrokeragesInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the five brokerages that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and three haSeptember 3, 2024 | marketbeat.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Sees Large Increase in Short InterestInovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) was the target of a large growth in short interest in August. As of August 15th, there was short interest totalling 2,920,000 shares, a growth of 9.0% from the July 31st total of 2,680,000 shares. Based on an average daily volume of 370,900 shares, the days-to-cover ratio is currently 7.9 days. Approximately 11.3% of the company's stock are short sold.September 1, 2024 | marketbeat.comINO Sep 2024 10.000 put (INO240906P00010000)August 22, 2024 | finance.yahoo.comInovio Pharmaceuticals Inc. stock rises Monday, still underperforms marketAugust 20, 2024 | marketwatch.comINO Aug 2024 20.000 call (INO240823C00020000)August 19, 2024 | finance.yahoo.comPrice T Rowe Associates Inc. MD Sells 137,501 Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)Price T Rowe Associates Inc. MD cut its holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) by 91.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,499 shares of theAugust 18, 2024 | marketbeat.comInovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $33.00 by Analysts at OppenheimerOppenheimer reduced their target price on shares of Inovio Pharmaceuticals from $40.00 to $33.00 and set an "outperform" rating for the company in a report on Monday.August 12, 2024 | marketbeat.comWe Think Inovio Pharmaceuticals (NASDAQ:INO) Needs To Drive Business Growth CarefullyAugust 11, 2024 | finance.yahoo.comVanguard Group Inc. Trims Position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)Vanguard Group Inc. lessened its holdings in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) by 91.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,594,385 shares of the biopharmaceuticaAugust 11, 2024 | marketbeat.comInovio Pharmaceuticals (NASDAQ:INO) Issues Earnings ResultsInovio Pharmaceuticals (NASDAQ:INO - Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.04). Inovio Pharmaceuticals had a negative return on equity of 88.13% and a negative net margin of 16,238.91%. The firm had revenue of $0.10 million during the quarter, compared to analysts' expectations of $0.10 million. During the same period in the prior year, the firm posted ($1.56) earnings per share.August 9, 2024 | marketbeat.comInovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $8.00 by Analysts at Royal Bank of CanadaRoyal Bank of Canada cut their price target on Inovio Pharmaceuticals from $11.00 to $8.00 and set a "sector perform" rating for the company in a report on Friday.August 9, 2024 | marketbeat.comInovio Pharmaceuticals: Maintaining Buy Rating Amid BLA Submission DelayAugust 9, 2024 | markets.businessinsider.comInovio Pharmaceuticals GAAP EPS of -$1.19 misses by $0.09, revenue of $0.1M misses by $0.02MAugust 9, 2024 | msn.comInovio Pharmaceuticals is about to announce earnings — here's what Wall Street expectsAugust 9, 2024 | markets.businessinsider.comInovio Pharmaceuticals Inc. Q2 Loss DecreasesAugust 9, 2024 | markets.businessinsider.comInovio Pharmaceuticals (INO) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | finance.yahoo.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and three have issued a buy rAugust 9, 2024 | marketbeat.comINO Stock Earnings: Inovio Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024August 8, 2024 | investorplace.comINOVIO Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 8, 2024 | prnewswire.comJacobs Levy Equity Management Inc. Sells 1,133,477 Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)Jacobs Levy Equity Management Inc. lowered its holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) by 98.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 16,497 shares of the biopharmaceutical company's stoAugust 3, 2024 | marketbeat.comINOVIO Reports Inducement Grant Under Inducement PlanAugust 1, 2024 | prnewswire.comInovio Pharmaceuticals (INO) to Release Earnings on ThursdayInovio Pharmaceuticals (NASDAQ:INO) will be releasing earnings after the market closes on Thursday, August 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=383119)August 1, 2024 | marketbeat.comIDH Inhibitor Market to Exhibit Significant Growth Rate During the Study Period (2020–2034) | DelveInsightJuly 31, 2024 | finance.yahoo.comInovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gainsJuly 25, 2024 | marketwatch.comInovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107July 25, 2024 | prnewswire.comINOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024July 25, 2024 | prnewswire.comInovio Pharmaceuticals (NASDAQ:INO) Receives "Neutral" Rating from HC WainwrightHC Wainwright reaffirmed a "neutral" rating and set a $15.00 target price on shares of Inovio Pharmaceuticals in a research report on Monday.July 15, 2024 | marketbeat.comSusquehanna Fundamental Investments LLC Makes New Investment in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)Susquehanna Fundamental Investments LLC acquired a new position in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 106,791 shares of the biopharmaceutJuly 14, 2024 | marketbeat.comINO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access PathwayJuly 11, 2024 | prnewswire.comGSA Capital Partners LLP Has $1.11 Million Holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)GSA Capital Partners LLP trimmed its holdings in Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) by 97.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,979 shares of the bioJuly 10, 2024 | marketbeat.comINOVIO Announces Appointment of Steven Egge as Chief Commercial OfficerJuly 2, 2024 | prnewswire.comINOVIO Reports Inducement Grant Under Inducement PlanJuly 1, 2024 | prnewswire.comINOVIO Added to Russell 2000® Index Effective July 1, 2024July 1, 2024 | prnewswire.comInovio Pharmaceuticals, Inc. (NASDAQ:INO) Shares Sold by Green Alpha Advisors LLCGreen Alpha Advisors LLC lowered its stake in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) by 91.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 36,417 shares of the biopharmaceutiJune 20, 2024 | marketbeat.com Get Inovio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Email Address This man believes TSLA will reach $500 a share… (Ad)Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future. To claim your copy, follow this link INO Media Mentions By Week INO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INO News Sentiment▼0.970.68▲Average Medical News Sentiment INO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INO Articles This Week▼12▲INO Articles Average Week Get Inovio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Surmodics News SI-BONE News Paragon 28 News Anika Therapeutics News ClearPoint Neuro News Tactile Systems Technology News Treace Medical Concepts News OraSure Technologies News Cerus News AngioDynamics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INO) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
